Skip to content

NICE Decision Support Unit

  • Home
  • Contact
    • Staff and Network
  • Training
    • Online training
  • Appraisal Specific
    • Alzheimer’s disease
    • Age-related macular degeneration
    • Ankylosing spondylitis
    • Breast cancer – lapatinib
    • Colorectal cancer – cetuximab
    • Crohn’s disease
    • Diabetes – dapagliflozin
    • Diabetes – liraglutide
    • Lung cancer – erlotinib
    • Lupus – belimumab
    • Macular oedema – bevacizumab
    • Myelodysplastic syndromes
    • Osteoporosis
    • Prostate cancer – degarelix
    • Renal cell carcinoma
    • Rheumatoid arthritis
    • Ribociclib
  • Methods Development
    • Accelerated Access Collaborative:
    • CHTE2020 Qualitative Evidence
    • CHTE2020 Sources and Synthesis of Evidence
    • The use of cost minimisation analysis for the appraisal of health technologies
    • Crossover and survival
    • EMU – Stata command
    • End of Life
    • EQ5D
    • EQ-5D-5L
    • Future unrelated costs
    • Managed Entry Agreements (MEA)
    • Mapping of EQ-5D
    • Mapping for Technology Appraisals
    • MCDA
    • Measuring and valuing health-related quality of life when sufficient data is not directly observed
    • Modelling carer health-related quality of life
    • NICE Methods Guide updates
    • Not cost-effective at £0
    • PFS-OS
    • QALY weighting
    • Quality assurance – models
    • Quality of Life in Cancer
    • Real World Data
    • Regression methods
    • Review of the STA process
    • Utility Values in Children
    • Value based pricing/assessment
    • Value of Information
    • Value of Innovation
  • Technical Support Documents
    • TSDs completed or currently in progress
    • TSD Summaries
    • Evidence Synthesis TSD series
    • Flexible Methods for Survival Analysis TSD
    • Multivariate meta-analysis TSD
    • Observational data TSD
    • Partitioned survival analysis TSD
    • Patient-level simulation TSD
    • Population-adjusted indirect comparisons (MAIC and STC)
    • Reviewing model parameters TSD
    • Survival analysis TSD
    • Treatment switching TSD
    • Utilities TSD series
  • Publications

Reviewing model parameters TSD


REVIEWING MODEL PARAMETERS TSD

A guide to identifying, selecting and using evidence to inform the model structure and its parameters, including recommendations for practice and reporting.

TSD 13: Identifying and reviewing evidence to inform the conceptualisation and population of cost-effectiveness models

TSD 13: TSD 13 One Page Summary

Tweets by @NICE_DSU

Subscribe for new reports

Check your inbox or spam folder to confirm your subscription.

  • Home
  • Contact
    • Staff and Network
  • Training
    • Online training
  • Appraisal Specific
    • Alzheimer’s disease
    • Age-related macular degeneration
    • Ankylosing spondylitis
    • Breast cancer – lapatinib
    • Colorectal cancer – cetuximab
    • Crohn’s disease
    • Diabetes – dapagliflozin
    • Diabetes – liraglutide
    • Lung cancer – erlotinib
    • Lupus – belimumab
    • Macular oedema – bevacizumab
    • Myelodysplastic syndromes
    • Osteoporosis
    • Prostate cancer – degarelix
    • Renal cell carcinoma
    • Rheumatoid arthritis
    • Ribociclib
  • Methods Development
    • Accelerated Access Collaborative:
    • CHTE2020 Qualitative Evidence
    • CHTE2020 Sources and Synthesis of Evidence
    • The use of cost minimisation analysis for the appraisal of health technologies
    • Crossover and survival
    • EMU – Stata command
    • End of Life
    • EQ5D
    • EQ-5D-5L
    • Future unrelated costs
    • Managed Entry Agreements (MEA)
    • Mapping of EQ-5D
    • Mapping for Technology Appraisals
    • MCDA
    • Measuring and valuing health-related quality of life when sufficient data is not directly observed
    • Modelling carer health-related quality of life
    • NICE Methods Guide updates
    • Not cost-effective at £0
    • PFS-OS
    • QALY weighting
    • Quality assurance – models
    • Quality of Life in Cancer
    • Real World Data
    • Regression methods
    • Review of the STA process
    • Utility Values in Children
    • Value based pricing/assessment
    • Value of Information
    • Value of Innovation
  • Technical Support Documents
    • TSDs completed or currently in progress
    • TSD Summaries
    • Evidence Synthesis TSD series
    • Flexible Methods for Survival Analysis TSD
    • Multivariate meta-analysis TSD
    • Observational data TSD
    • Partitioned survival analysis TSD
    • Patient-level simulation TSD
    • Population-adjusted indirect comparisons (MAIC and STC)
    • Reviewing model parameters TSD
    • Survival analysis TSD
    • Treatment switching TSD
    • Utilities TSD series
  • Publications
NICE Decision Support Unit Proudly powered by WordPress